SABCS 2023 | Phase II study of Bria-IMT in metastatic breast cancer

Saranya Chumsri, MD, Mayo Clinic, Jacksonville, FL, gives an overview of data coming from a study (NCT03328026) of Bria-IMT, an allogenic human cell line with antigen presenting activity designed to overcome the immune-suppressive tumor microenvironment. This ongoing prospective, randomized Phase II tiral evaluated Bria-IMT with a PD-1check point inhibitor in patients with heavily pre-treated metastatic breast cancer. An interim, exploratory analysis showed that sequencing of a checkpoint inhibitor with Bria-IMT is associated with differential clinical outcome trends but was not statistically significant. Clinical benefit was demonstrated for both treatment schedules among patients with inducible delayed-type hypersensitivity skin test (DTH) reactions. A randomized phase 3 pivotal registrational trial is ongoing to further evaluate these findings. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.